STAAR Surgical (NASDAQ:STAA) executives emphasized a return to execution in fiscal 2026 after what they described as a ...
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses ...
The average one-year price target for STAAR Surgical (NasdaqGM:STAA) has been revised to $20.12 / share. This is a decrease of 13.10% from the prior estimate of $23.15 dated February 21, 2026. The ...
Regarding “Texas lawmakers are moving bills to kill STAAR. But the test persists.,” (Aug. 25): The Chronicle’s recent editorial suggests House Bill 8 and Senate Bill 9 amount to little more than a ...
Two of Staar Surgical Co.’s largest shareholders are opposing its proposed sale to Alcon Inc., putting the $1.5 billion deal at risk. Broadwood Partners L.P., which holds a 27.5% stake in Staar, last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results